FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
December 19, 2022 at 13:48 PM EST
TheFDA removed its partial clinical holdonBluebird bio Inc's(NASDAQ: BLUE) study for patients under the ...